Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF10136, Administered Via Dry Powder Inhaler, After Single Ascending Dose in Healthy Subjects, Multiple Ascending Doses in Mild Asthmatic Subjects and Followed by a Repeated Dose in One Cohort of Moderate-to-Severe Asthmatic Subjects

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma. The study includes single-dose, multiple-dose, and repeated-dose treatment periods and will also characterize the pharmacokinetic profile of CHF10136.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

⁃ For PART 1 - SAD

• Healthy male or female participant ≥18 and ≤55 years of age

• Body mass index (BMI) ≥18 and ≤30 kg/m2 at screening and weight at least 50 kg;

• Good physical and mental status, determined via assessment of medical history at screening and physical examination at screening and prior to randomisation;

• Spirometry measurements within normal limits at screening and prior to randomisation based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) interpretative strategies for spirometry. The forced expiratory volume in the first second (FEV1) must be \>80% of predicted normal value and the FEV1/Forced Vital Capacity (FVC) ratio must be \>0.7.

• Male and Female participants willing and able to comply with study procedures

⁃ For PART 2 - MAD

• Male or female participants ≥18 and ≤55 years of age at screening

• BMI ≥18 and ≤32 kg/m2 at screening and weight at least 50 kg;

• Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.

• Not currently receiving regular maintenance therapy for asthma, with no changes to treatment within \<4 weeks prior to screening, and no exposure to ICS in the 12 weeks prior to screening including ICS reliever therapy;

• Pre-bronchodilator FEV1 ≥70% of predicted at the screening visit and prior to randomisation;

• Male and Female participants willing and able to comply with study procedures

⁃ For PART 3 - REPEATED DOSE

• Male or female participants ≥18 and ≤65 years of age at screening

• BMI ≥18 and ≤35 kg/m2 at screening and weight at least 50 kg;

• Physician-diagnosed asthma for at least 6 months and before the age of 50 years. Documented evidence of one of the confirmed variable expiratory airflow criteria, as per the GINA 2026 guidelines, is required within 10 years prior to screening.

• On a stable asthma treatment regimen of medium to high dose Inhaled Corticosteroids/Long-Acting Beta2-Agonists(ICS/LABA) (as defined by GINA 2026 guidelines) with no changes to treatment within 12 weeks prior to screening.

• Pre-bronchodilator FEV1 ≥40% and ≤90% of predicted at the screening visit and prior to randomisation;

• Asthma Control Questionnaire - 6 Items (ACQ-6) score of 0.5 to 3.0 at screening and prior to randomisation;

• Male and Female participants willing and able to comply with study procedures

Locations
Other Locations
United Kingdom
Fortrea Leeds CRU
RECRUITING
Leeds
hVIVO
NOT_YET_RECRUITING
London
MEU
NOT_YET_RECRUITING
Manchester
Contact Information
Primary
Chiesi Clinical trial Info clinicaltrials_info@chiesi.com
clinicaltrials_info@chiesi.com
+390521279715
Time Frame
Start Date: 2026-10-02
Estimated Completion Date: 2027-12-27
Participants
Target number of participants: 120
Treatments
Experimental: CHF10136.
Participants receive CHF10136 administered via dry powder inhaler. Doses vary according to study cohort.
Placebo_comparator: Placebo
Participants receive placebo powder for inhalation administered via dry powder inhaler.
Related Therapeutic Areas
Sponsors
Leads: Chiesi Farmaceutici S.p.A.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials